Arbutus Biopharma Logo
Tekmira Announces New Preclinical Data from Anti-Viral Programs
November 12, 2013 17:00 ET | Arbutus Biopharma Corporation
Results Demonstrate Survival Following Lethal Infection When Treatment Is Delayed VANCOUVER, British Columbia, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR)...
Arbutus Biopharma Logo
Tekmira's Partner Initiates Phase III Trial With LNP-Enabled Patisiran (ALN-TTR02)
November 10, 2013 23:28 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 10, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Arbutus Biopharma Logo
Tekmira Conference Call and Webcast Advisory: Corporate Update and Third Quarter Financial Results
November 07, 2013 17:04 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Arbutus Biopharma Logo
Tekmira Announces Closing of Underwriters' Full Over-Allotment Option
November 01, 2013 11:12 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 1, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Arbutus Biopharma Logo
Preclinical Data Presented at Scientific Symposium Demonstrates That mRNA is Efficiently Delivered Using Tekmira's LNP
October 24, 2013 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Arbutus Biopharma Logo
Tekmira Announces Completion of US$30 Million Public Offering of Common Stock
October 22, 2013 10:16 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Arbutus Biopharma Logo
Tekmira Prices Public Offering of Common Stock
October 17, 2013 08:48 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 17, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Arbutus Biopharma Logo
Tekmira Announces Proposed Public Offering of Common Stock
October 16, 2013 16:01 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Arbutus Biopharma Logo
Tekmira Provides Corporate Update on RNAi Therapeutics Pipeline
October 08, 2013 16:00 ET | Arbutus Biopharma Corporation
Tekmira Builds Upon Extensive Experience in Anti-Viral Therapeutics by Adding Therapeutics Addressing Hepatitis B and Marburg Virus to Product Pipeline TKM-ALDH2, an RNAi Therapeutic for Alcohol...
Arbutus Biopharma Logo
Tekmira Appoints Bruce Cousins as Executive Vice President and Chief Financial Officer
October 07, 2013 16:00 ET | Arbutus Biopharma Corporation
VANCOUVER, B.C., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that Mr....